Changwei Liu
State Key Laboratory Of Chemical Engineering
Shanghai, China
Shanghai, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
NSD2 inhibits the expression of PD-L1 via oxidative phosphorylation to control immune surveillance in hepatocellular carcinoma.
Journal: Cell death & disease
Published: July 19, 2025
NSD2 promotes cell durotaxis and drives the transition from polycystic kidney disease to tubulocystic renal cell carcinoma through integrin/FAK/AKT signaling.
Journal: Oncogene
Published: February 07, 2025
Multilevel Regulation of NF-κB Signaling by NSD2 Suppresses Kras-Driven Pancreatic Tumorigenesis.
Journal: Advanced science (Weinheim, Baden-Wurttemberg, Germany)
Published: December 03, 2023
Setd2 deficiency promotes gastric tumorigenesis through inhibiting the SIRT1/FOXO pathway.
Journal: Cancer letters
Published: August 10, 2023
Loss of SETD2 aggravates colorectal cancer progression caused by SMAD4 deletion through the RAS/ERK signalling pathway.
Journal: Clinical and translational medicine
Published: June 15, 2023
SETD2 deficiency promotes renal fibrosis through the TGF-β/Smad signalling pathway in the absence of VHL.
Journal: Clinical and translational medicine
Published: April 10, 2023
SETD2 deficiency accelerates sphingomyelin accumulation and promotes the development of renal cancer.
Journal: Nature communications
Published: February 19, 2023
SETD2 epidermal deficiency promotes cutaneous wound healing via activation of AKT/mTOR Signalling.
Journal: Cell proliferation
Published: January 20, 2021
Showing 1-9 of 9
Last Updated: 09/26/2026